As Fierce Biotech reports, Henri Termeer of Genzyme stands to rake in up to $221 M from the Genzyme deal with Sanofi. This includes $145.9 M for his stock, plus $12.5 M for change of control specified in his contract, plus up to another $62.8 M if the CVRs from the Genzyme deal payout at their maximum value.
Not a bad day's work and a far cry from being potentially ousted from the company by Carl Icahn only last year. Quite a rise from adversity.
Posted by Bruce Lehr March 7th 2011.